Question

把以下文章翻译成英文

文章：目的：通过对降血脂药物的市场调查研究特别是他汀类降血脂药物，得到他汀类药物市场的现状，有助于给国内制药企业在策划他汀类药物市场销售上提供依据。研究方法：个案法、文献法、拜访法收集资料。成果：他汀类药物占据降血脂药物绝大部分市场份额，其中五大他汀类代表药也占据了大部分他汀类药物的市场份额，而且这五大代表药的主要市场份额分别被不同的跨国公司所占有。这五大代表药分别是排名第一位的是辛伐他汀，占69.2%的市场份额，第二位的是阿托伐他汀，占11.9%的市场份额；以下依次是普伐他汀（11.3%）、氟伐他汀（6.8%）、洛伐他汀（约1%）。分别所对应的领导这五大代表药的公司是美国默克公司、美国辉瑞公司、日本三共制药株式会社、瑞士诺华公司、美国默克公司，这其中默克公司也是同时拥有两大他汀类药物的公司。结论：他汀类降血脂药物市场是一个很诱人同时也是一个很可怕的市场，通过资料及讨论可以看出他汀类药物的市场份额几乎都被国外的大公司所占有，根本没有我们的生存空间。原因在于国内的制药企业生产的他汀类药物降血脂的长短期效果与进口药物无法相比，而且在药物宣传的力度上还不够。具体的说，就是要加强我们药物的质量、营销渠道，如OTC市场、医院的学术推广、借助医药公司中间商等等。要想在他汀类市场获得一席之地需从小的他汀类如，洛伐他汀做起，因为他的垄断不是特别严重。

Answer 1

Goal: Through to falls the blood fats medicine the market survey research is specially his sandbank class falls the blood fats medicine, obtains his sandbank class medicine market present situation, is helpful in gives the domestic drugs manufacture enterprise in to plan in his sandbank class medicine market sale to provide the basis. Research technique: Case law, literature law, visiting law data collection. Achievement: His sandbank class medicine hold fell the blood fats medicine major part market share, in which five is big his sandbank class to represent the medicine also to occupy the majority of his sandbank class medicine market share, moreover these five representatives the medicine main market share is held separately by the different multinational corporation. These five big respectively is places first on behalf of the medicine is Xin cuts down his sandbank, occupies 69.2% market shares, second is the atropic cuts down his sandbank, occupies 11.9% market shares; The following is in turn Pu cuts down his sandbank (11.3%), the fluorine cuts down his sandbank (6.8%), the Luo river cuts down his sandbank (approximately 1%). The distinction corresponds the leadership these five big on behalf of the medicine company is the American silent gram company, American Splendor Auspicious Company, Japan three altogether manufactures drugs the joint-stock company, Switzerland promises Chinese Corporation, the American silent gram company, this silent gram company also is simultaneously has two is big his sandbank class medicine the company. Conclusion: His sandbank class falls the blood fats medicine market is very attractive simultaneously also is a very fearful market, may see his sandbank class medicine through the material and the discussion the market share nearly all to hold by the overseas big company, simply does not have our existing space. The reason lies in his sandbank class medicine which the domestic drugs manufacture enterprise produces to fall the blood fats the length period of validity fruit and the import medicine is unable to compare, moreover in medicine propaganda dynamics also insufficient. Concrete saying, is must strengthen our medicine the quality, the marketing channel, like OTC market, hospital academic promotion, with the aid of medicine company middle men and so on. Must want to obtain the small space in his sandbank class market to have since childhood his sandbank as for example, the Luo river cuts down his sandbank to start, because his monopoly is not specially serious.

Answer 2

Through market research, in particular the cholesterol drugs is statins Hypolipidemic drug received statins drug market status, He planned to help domestic enterprises in the pharmaceutical drugs statins on the market to provide a basis. Methods : case law, literature, call data was collected. He Ting results : Hypolipidemic drug occupy most of the market share of drugs, representatives of the five major types of drugs which he Ting Ting he has occupied most of the market share for drugs, and representatives of the five drugs were a major share of the market share of multinational companies are different. Representatives of the five major drug simvastatin were ranked first, accounting for 69.2% of the market share. Atorvastatin is the second largest, accounting for 11.9% of the market share; Following are the pravastatin (11.3%). fluvastatin (6.8%), lovastatin (about 1%). Corresponding to each of the five leading companies in the United States on behalf of drug companies Merck, Pfizer U.S. companies A total of Pharmaceutical Co. Ltd. of Japan, China Ruishinuo Corporation and Merck. This is also the same time, Merck has two statins drug companies. Conclusion : statins Hypolipidemic drug market is a very attractive market but also a very frightening. Ting he can be seen through the information and discuss the drug's market share in almost all large companies by foreign shares, We did not survive. The reason is that the domestic production of pharmaceutical drugs dislipidemias statins long-term and short-term effects can not be compared with the imported medicine, Moreover, the drug is still not enough publicity efforts. Specifically, it is necessary to enhance the quality of our drugs, and marketing channels, such as the OTC market, the promotion of academic hospitals, pharmaceutical companies through brokers and so on. He was in the market place in order to take statins from statins such as lovastatin start. He is not particularly serious because the monopoly.

Answer 3

Through market research, in particular the cholesterol drugs is statins Hypolipidemic drug received statins drug market status, He planned to help domestic enterprises in the pharmaceutical drugs statins on the market to provide a basis. Methods : case law, literature, call data was collected. He Ting results : Hypolipidemic drug occupy most of the market share of drugs, representatives of the five major types of drugs which he Ting Ting he has occupied most of the market share for drugs, and representatives of the five drugs were a major share of the market share of multinational companies are different. Representatives of the five major drug simvastatin were ranked first, accounting for 69.2% of the market share. Atorvastatin is the second largest, accounting for 11.9% of the market share; Following are the pravastatin (11.3%). fluvastatin (6.8%), lovastatin (about 1%). Corresponding to each of the five leading companies in the United States on behalf of drug companies Merck, Pfizer U.S. companies A total of Pharmaceutical Co. Ltd. of Japan, China Ruishinuo Corporation and Merck. This is also the same time, Merck has two statins drug companies. Conclusion : statins Hypolipidemic drug market is a very attractive market but also a very frightening. Ting he can be seen through the information and discuss the drug's market share in almost all large companies by foreign shares, We did not survive. The reason is that the domestic production of pharmaceutical drugs dislipidemias statins long-term and short-term effects can not be compared with the imported medicine, Moreover, the drug is still not enough publicity efforts. Specifically, it is necessary to enhance the quality of our drugs, and marketing channels, such as the OTC market, the promotion of academic hospitals, pharmaceutical companies through brokers and so on. He was in the market place in order to take statins from statins such as lovastatin start. He is not particularly serious because the monopoly.